Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

gemcitabine

- PMLiVE

Lilly’s donanemab shows promise in early symptomatic Alzheimer’s comparator study

Brain amyloid clearance was achieved in 37.9% of patients treated with the investigational antibody

- PMLiVE

Gilead’s Biktarvy received EC approval for the treatment of HIV in paediatric populations

After changing to Biktarvy, 98% of patients in two groups were suppressed at week 48

- PMLiVE

MHRA approves LEO Pharma’s Adtralza for adolescent patients with atopic dermatitis

The changes to the terms were also approved by the EC in October

regeneron headquarters

Regeneron’s Libtayo granted EC approval for recurrent or metastatic cervical cancer

A phase 3 trial demonstrated a 31% reduction in the risk of death compared to chemotherapy

- PMLiVE

AbbVie’s Skyrizi receives EC approval for active Crohn’s disease

The approval makes Skyrizi the first specific IL-23 inhibitor as a Crohn's treatment in the EU

- PMLiVE

BeiGene’s Brukinsa receives EC approval for chronic lymphocytic leukaemia

The drug showed better results than Imbruvica, a current standard of care treatment

- PMLiVE

Sanofi’s Enjaymo receives EC approval for rare autoimmune haemolytic anaemia

Cold agglutinin disease affects around 12,000 people in the US, Europe and Japan

- PMLiVE

Eli Lilly set to launch Tempo Personalized Diabetes Management Platform

Users can use the app to log insulin doses, set reminders and access education resources

- PMLiVE

Boehringer and Lilly’s Jardiance shows promise in phase 3 chronic kidney disease trial

Jardiance reduced disease progression and cardiovascular death by 28%

- PMLiVE

AstraZeneca/Sanofi’s Beyfortus receives EC approval for prevention of RSV in infants

The decision makes the antibody the first broadly protective option for this age population

- PMLiVE

BeiGene’s Brukinsa receives EC approval for marginal zone lymphoma

The BTK inhibitor was also granted an additional year of marketing protection

- PMLiVE

Eli Lilly and Purdue sign $92.5m deal for pharma manufacturing scholarships

Participating students with be able to compete for a role at the company following graduation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links